Patent Issued for Dalbavancin for the Treatment of Complicated Skin and Soft Tissue Infections
Jun 2, 2005 - 1:50:38 PM
Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that the United States Patent and Trademark Office issued patent number 6,900,175 entitled "Methods of Administrating Dalbavancin For Treatment Of Bacterial Infections."
The patent, which will expire in December 2023, relates to a novel dosing regimen for dalbavancin. The dalbavancin New Drug Application (NDA) for the treatment of complicated skin and soft tissue infections (cSSTIs) including the most difficult to treat strain of staphylococcus, methicillin-resistant staphylococcus aureus (MRSA) is currently under review with the U.S. Food and Drug Administration (FDA).
Dalbavancin is a novel second-generation lipoglycopeptide agent that belongs to the same class as vancomycin. Vancomycin is one of the few treatments available to hospital patients infected with difficult-to-treat strains of Staphylococcus bacteria, or Staph known as MRSA (methicillin- resistant Staphylococcus aureus) and MRSE (methicillin-resistant Staphylococcus epidermidis). Dalbavancin has been specifically designed as an improved alternative to vancomycin.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )